| Revue: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000413456 |
| ISSN: | 1665-2681 |
| Autores: | Cardoso, Ana C1 Beaugrand, Michel2 Ledinghen, Victor de3 Douvin, Catherine4 Poupon, Raoul5 Trinchet, Jean-Claude2 Ziol, Marianne5 Bedossa, Pierre6 Marcellin, Patrick1 |
| Instituciones: | 1Hopital Beaujon, Service d’Hepatologie, Clichy, París. Francia 2Hopital Jean Verdier, Department of Hepatology, Bondy, Seine-Saint-Denis. Francia 3Hopital Haut-Leveque, Department of Hepatology, Bordeaux, Gironde. Francia 4Hopital Henri Mondor, Department of Hepatology, Creteil, Val-de-Marne. Francia 5Hospital Group Paris-Seine-Saint Denis, Department of Anatomy and Pathology, Bondy, Seine-Saint-Denis. Francia 6Hopital Beaujon, Department of Anatomy Pathology, Clichy, París. Francia |
| Año: | 2015 |
| Periodo: | Nov-Dic |
| Volumen: | 14 |
| Número: | 6 |
| Paginación: | 826-836 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | A novel controlled attenuation parameter (CAP) using the signals acquired by the FibroScan® has been developed as a method for evaluating steatosis. The aim of this study is to assess the performance of the CAP for the detection and quantification of steatosis in patients with chronic hepatitis B (CHB). Material and methods. 136 subjects with CHB underwent liver biopsy and FibroScan® within 60 days. CAP was evaluated retrospectively using raw FibroScan® data. Steatosis was graded as follows: S0 (steatosis < 10% of hepatocytes), S1 (10 to < 30%), S2 (30 to < 60%) or S3 (≥ 60%). Performance was evaluated by area under the receiver operating characteristic (AUROC) curve. Results. Proportions of each steatosis grade (S0-S3) were 78, 10, 9 and 3%, respectively. Using univariate analysis, liver stiffness measurement (LMS) significantly correlated with fibrosis stage (τ = 0.43; P < 10-10), sex, necro-inflammatory activity, steatosis, age, NASH, and perisinusoidal fibrosis, and with liver fibrosis stage (P < 10-8) and perisinusoidal fibrosis (P = 0.008) using multivariate analysis. CAP correlated with steatosis (τ = 0.38, P < 10-7), body mass index, NASH, fibrosis and perisinusoidal fibrosis using univariate analysis, but only steatosis (P < 10-10) and perisinusoidal fibrosis (P = 0.002) using multivariate analysis. AUROCs for LSM were: 0.77 (0.69-0.85), 0.87 (0.80-0.95), and 0.93 (0.83-1.00), respectively, for fibrosis stages F ≥ 2, F ≥ 3 and F = 4. AUROCs for CAP were: 0.82 (0.73-0.92), 0.82 (0.69-0.95), and 0.97 (0.84-1.00) for ≥ S1, ≥ S2 and S3 steatosis, respectively. Conclusions. In conclusion CAP is a novel, accurate non-invasive tool and may be suitable for detecting and quantifying steatosis in CHB patients |
| Disciplinas: | Medicina |
| Palabras clave: | Gastroenterología, Hepatitis B, Hepatitis crónica, Esteatosis, Estadificación, Elastografía |
| Keyword: | Medicine, Gastroenterology, Hepatitis B, Chronic hepatitis, Steatosis, Staging, Elastography |
| Texte intégral: | Texto completo (Ver PDF) |
